Tags

Type your tag names separated by a space and hit enter

No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
J Clin Psychiatry. 1995 Apr; 56(4):167-70.JC

Abstract

BACKGROUND

There are few objective guidelines for the clinician in the choice of antiparkinsonian drugs, even though these drugs are a heterogeneous group. We compared the effect of biperiden (M1 selective anticholinergic) and amantadine (dopaminergic) on neuroleptic-induced parkinsonian extrapyramidal symptoms (EPS) and tardive dyskinesia (TD)-type involuntary movements.

METHOD

Thirty-two schizophrenic (DSM-III-R) inpatients on long-term stable antipsychotic and trihexyphenidyl treatment entered the study. Antipsychotics were kept constant, but trihexyphenidyl was replaced by placebo under single-blind conditions for 1 week, and the the patients were randomly assigned to either amantadine 100 mg b.i.d. or biperiden 2 mg b.i.d. treatment under double-blind conditions for 2 weeks. After a second 1-week placebo period, the test drugs were crossed over under double-blind conditions. Assessments of tardive dyskinesia (Abnormal Involuntary Movement Scale [AIMS]) and of parkinsonian extrapyramidal side effects (Simpson-Angus Neurologic Rating Scale) were made pretreatment and posttreatment.

RESULTS

Twenty-six patients completed all study procedures. Amantadine and biperiden were equally effective in relieving neuroleptic-induced EPS and did not exacerbate TD-type movements. AIMS scores during treatment were significantly lower than during placebo period. The findings were similar in patients with diagnosable TD.

CONCLUSION

Amantadine and biperiden have similar effects on neuroleptic-induced EPS and TD and may ameliorate mild TD.

Authors+Show Affiliations

Flugelman (Mazra) Psychiatric Hospital, Doar Na Ashrat, Israel.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7713856

Citation

Silver, H, et al. "No Difference in the Effect of Biperiden and Amantadine On Parkinsonian- and Tardive Dyskinesia-type Involuntary Movements: a Double-blind Crossover, Placebo-controlled Study in Medicated Chronic Schizophrenic Patients." The Journal of Clinical Psychiatry, vol. 56, no. 4, 1995, pp. 167-70.
Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry. 1995;56(4):167-70.
Silver, H., Geraisy, N., & Schwartz, M. (1995). No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. The Journal of Clinical Psychiatry, 56(4), 167-70.
Silver H, Geraisy N, Schwartz M. No Difference in the Effect of Biperiden and Amantadine On Parkinsonian- and Tardive Dyskinesia-type Involuntary Movements: a Double-blind Crossover, Placebo-controlled Study in Medicated Chronic Schizophrenic Patients. J Clin Psychiatry. 1995;56(4):167-70. PubMed PMID: 7713856.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. AU - Silver,H, AU - Geraisy,N, AU - Schwartz,M, PY - 1995/4/1/pubmed PY - 1995/4/1/medline PY - 1995/4/1/entrez SP - 167 EP - 70 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 56 IS - 4 N2 - BACKGROUND: There are few objective guidelines for the clinician in the choice of antiparkinsonian drugs, even though these drugs are a heterogeneous group. We compared the effect of biperiden (M1 selective anticholinergic) and amantadine (dopaminergic) on neuroleptic-induced parkinsonian extrapyramidal symptoms (EPS) and tardive dyskinesia (TD)-type involuntary movements. METHOD: Thirty-two schizophrenic (DSM-III-R) inpatients on long-term stable antipsychotic and trihexyphenidyl treatment entered the study. Antipsychotics were kept constant, but trihexyphenidyl was replaced by placebo under single-blind conditions for 1 week, and the the patients were randomly assigned to either amantadine 100 mg b.i.d. or biperiden 2 mg b.i.d. treatment under double-blind conditions for 2 weeks. After a second 1-week placebo period, the test drugs were crossed over under double-blind conditions. Assessments of tardive dyskinesia (Abnormal Involuntary Movement Scale [AIMS]) and of parkinsonian extrapyramidal side effects (Simpson-Angus Neurologic Rating Scale) were made pretreatment and posttreatment. RESULTS: Twenty-six patients completed all study procedures. Amantadine and biperiden were equally effective in relieving neuroleptic-induced EPS and did not exacerbate TD-type movements. AIMS scores during treatment were significantly lower than during placebo period. The findings were similar in patients with diagnosable TD. CONCLUSION: Amantadine and biperiden have similar effects on neuroleptic-induced EPS and TD and may ameliorate mild TD. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/7713856/No_difference_in_the_effect_of_biperiden_and_amantadine_on_parkinsonian__and_tardive_dyskinesia_type_involuntary_movements:_a_double_blind_crossover_placebo_controlled_study_in_medicated_chronic_schizophrenic_patients_ L2 - http://www.diseaseinfosearch.org/result/6999 DB - PRIME DP - Unbound Medicine ER -